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Abstract 
Purpose: To prepare and characterize transdermal films of diclofenac diethanolamine as a safer and 
more effective alternative than the sustained release (SR) tablet equivalent for prolonged relief from 
pain and inflammation in arthritis.  
Methods: Transdermal films of diclofenac were prepared using sodium carboxymethyl cellulose and 
polyvinyl pyrrolidone K30, with turpentine oil and sesame oil as penetration enhancers. The films were 
characterized for physicochemical properties and for ex vivo permeation in a randomized clinical trial 
(RCT) for analgesic activities in arthritic patients.  
Results: The transdermal films were uniform in weight and thickness, flat, with high drug content (94.40 
± 1.04 to 98.62 ± 1.08 %) and with high folding endurance (149 ± 9.09 to 192 ± 10.12). Drug permeation 
through excised rat abdominal skin was prolonged. Films containing penetration enhancers showed 
higher ex vivo drug permeation than those without the enhancer; furthermore, drug permeation 
increased with increase in the concentration of enhancer. The films were non-irritating to the skin. In 
RCT, F3 (containing turpentine oil, 1 %v/w) decreased the pain score from 9.87 ± 1.14 to 4.94 ± 0.78 
units, compared with the SR tablet (once daily) which decreased pain from 9.59 ± 0.42 to 6.49 ± 1.20 
units, 48 h post-administration. Turpentine oil showed better permeation enhancement than sesame oil 
in the transdermal films.  
Conclusion: Transdermal films of diclofenac, formulated with permeation enhancers, may have greater 
therapeutic advantages over conventional oral tablets in terms of prolonged release and improvement of 
patient compliance in rheumatoid arthritis.   
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Rheumatoid arthritis (RA), an autoimmune and 
progressive systemic inflammatory disease, 
affects a huge number of people worldwide. RA 
adversely affects the quality of life and normal 
function, especially 10 years post-diagnosis. The 
immune system attacks joint tissues and 
potentially other body parts for unknown causes. 
RA is characteristically associated with fatigue, 
chronic joint pain, and prolonged stiffness (even 
after rest) [1,2]. Although there is no cure for RA, 
novel effective drugs are being explored and are 
available to treat the disease and prevent joint 
deformities [3,4]. Managing the moderate to 
severe chronic pain and inflammation, as well as 
improving the quality of life in arthritic patients, is 
the most challenging and important goal of anti-
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arthritic therapy. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are prescribed frequently for the 
management of pain and local inflammation 
(similar to gout) [5].  
 
Conventional oral administration of NSAIDs is 
associated with serious adverse effects such as 
gastrointestinal (GI) bleeding, renal dysfunction, 
blood pressure elevation, and significant plasma-
drug level fluctuations, increasing the risk of 
overdose. Among the side effects reported, 
upper GI bleeding and GI toxicity are the most 
common [6]. Moreover, a high dosing frequency 
is desired for the majority of NSAIDs to provide 
prolonged relief from pain and inflammation.  
 
To overcome these limitations, various novel 
approaches of drug delivery for NSAIDs have 
been investigated. Topical or transdermal drug 
delivery of NSAIDs is one of the most widely 
investigated and is a potential alternative for 
delivering NSAIDs. For the management of pain 
and inflammation in RA, localized drug delivery 
with polymeric dosage forms and delivery 
systems such as gels/creams/ointments, 
implants/in situ gels, and transdermal patches 
can deliver the drug in microenvironments of the 
bones, joints, or affected tissue and ligaments. 
The topical or transdermal drug delivery of 
NSAIDs has many advantages, such as 
localized/higher site specific delivery, prolonged 
drug release, avoidance of hepatic first pass, no 
gastric discomfort side effects, no interaction with 
the other drugs in multi-drug therapies, and 
better patient compliance [7,8]. Factors such as 
cytokines, prostaglandins including 
cyclooxygenase-2, and leukotrienes are 
regulated by activation of the transcription factor 
nuclear factor-κB and mediate pain and 
inflammation in RA. Therefore, any drug that can 
suppress the expression of tumor necrosis 
factor-α or suppress the activation of NF-κB may 
be a potential anti-arthritic drug [9].   
 
Diclofenac is an NSAID used for the effective 
management of RA. Diclofenac, a carboxylic acid 
derivative, acts as a selective COX-2 inhibitor 
and is the most widely used NSAID for managing 
pain and inflammation after orthopedic 
injury/fracture, arthritis, toothache, and 
dysmenorrhea. Studies have reported that the 
efficacy of diclofenac (even at a low dosage of 
100 mg/day) is as effective as other newer 
analgesics used in arthritis. Diclofenac shows GI 
irritation, peptic ulceration, and GI bleeding. 
Diclofenac also has a short half-life (4 h). The 
poor water solubility of diclofenac leads to poor 
dissolution and low bioavailability [10,11].  
 
Among the various transdermal drug delivery 
systems, transdermal films/patches are the most 
recently developed dosage forms, which are 
well-suited for chronic pain and inflammation 
management of arthritic patients [12]. An ideal 
transdermal patch should have flexibility, 
elasticity, and softness. However, at the same 
time it must have sufficient strength to follow the 
body contours.  It must also possess good 
adhesive strength for prolonged retention on the 
skin for the desired duration of action. The use of 
various permeation enhancers can improve drug 
flux across the skin. In addition, various 
chemicals are used to improve penetration 
across the skin, including alcohols, terpenes, and 
surfactants [13,14].  
 
Therefore, the present study aims to develop and 
characterize transdermal films of diclofenac 
using two different permeation enhancers (in two 
different concentrations). For topical use, the 
diethanolamine salt of diclofenac is preferred 
over potassium or sodium salt. Thus, diclofenac 
diethanolamine was used in this report. Among 
the permeation enhancers, sesame oil and 
turpentine oil were used. The performance of the 
prepared films was compared with that of those 
without enhancer. The prepared films were 
characterized for various physicochemical 






Diclofenac diethanolamine, sodium 
carboxymethyl cellulose (SCMC)-low viscosity 
grade, polyvinyl pyrrolidone K-30 (PVP-K30), 
turpentine oil, sesame oil, and carrageenan were 
purchased from Sigma Aldrich, USA. All other 
chemicals were of analytical grade.  
 
Preparation of diclofenac transdermal films  
 
Matrix type transdermal films loaded with 
diclofenac were prepared using the solvent 
evaporation technique (Table 1). 
 
An aqueous solution of polyvinyl alcohol (4 
%w/v) was used to prepare the backing 
membrane. The aqueous solution of polyvinyl 
alcohol (PVA) was poured onto flat bottom teflon 
molds, followed by drying at 45 °C for 3 h. 
 
The required amount of polymers (SCMC and 
PVP K-30) was dissolved in distilled water with 
constant stirring at 300 rpm. Diclofenac (drug), 
propylene glycol (plasticizer), turpentine oil, and 
sesame oil (as permeation enhancers) were 
added to this solution with continuous stirring. 
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 Table 1: Composition of the transdermal diclofenac patch 
 
Ingredient Formulation 
 F1 F2 F3 F4 F5 
Diclofenac Diethanolamine (% w/w)* 15 15 15 15 15 
SCMC: PVP** 1:1 1:1 1:1 1:1 1:1 
Di-n-butylphthalate (% w/w)* 30 30 30 30 30 
Turpentine oil (% v/w) - 0.5 1.0 - - 
Sesame oil (% v/w) - - - 0.5 1.0 
              * % W/w of total weight of polymer; ** total weight of polymers taken was 500 mg 
 
After uniform mixing, the solution was added to 
the backing membrane and kept on a flat 
surface. These flat bottom teflon molds 
containing drug-polymer solution were kept at 40 
°C for 12 h in a hot air oven. The prepared cast 
film was cut into transdermal patches of 2 × 2 
cm, packed properly, and then stored in a 
desiccator until further use.  
 
Physicochemical characterization of prepared 
films 
 
The films were evaluated for thickness, weigh 
uniformity, folding endurance, and drug content. 
The average thickness (of three different sites) of 
the film was determined using a screw-gauge in 
a circular cast (n = 3). The weight of each patch 
(5 cm2) was determined (n = 3). Folding 
endurance was determined by repeatedly folding 
a small strip (2 × 2 cm2) of film at the same point 
until it broke.  
 
For the determination of drug content, the patch 
from each film was dissolved in 100 mL of 
methanol with continuous stirring for 2 h (n = 3). 
The solutions were filtered, diluted (100 times), 
and analyzed spectrophotometrically (Perkin 
Elmer, Lambda 25, US). 
 
Ex vivo permeation studies 
 
The ex vivo permeation studies of the diclofenac 
films were performed in a modified Franz 
diffusion cell through excised rat abdominal skin. 
A patch of 2 × 2 cm2 of each formulation was 
placed in close contact with excised skin. The 
receptor compartment of the diffusion cell was 
filled with 25 mL of pH 7.4 phosphate buffer. The 
media was maintained at 37 ± 1°C with agitation 
at 100 rpm. The samples (taken at different time 
intervals and with the same volume of fresh 
prewarmed media replaced in the receptor 
compartment) were analyzed 
spectrophotometrically.  
 
In vivo studies 
 
Healthy male Wistar rats (weight, 200–250 g) 
were used in the studies. The rats were kept in 
cages under standard environmental conditions 
of light and temperature and were allowed free 
access to drinking water and standard diet. 
Protocols of the animal study were approved by 
the Animal Ethical Committee (approval no. 
2015/4.21) and the study was performed 
according to international guidelines [15]. 
 
Primary skin irritation test  
 
For the primary skin irritation test, healthy male 
Wistar rats were divided into three groups of six 
rats each. A 4-cm2 area of the dorsal portion of 
all rats was shaved and wiped with surgical spirit. 
The test formulation was applied over the 
respective test sites. The test sites were 
observed for any toxic side effects, erythema, 
and edema on the skin surface for 48 h after 
application in comparison to a standard irritant (2 
% formalin solution) and control (blank film only).   
 
Clinical evaluation of selected films  
 
Patients in the orthopedic ward (OPD and IPD) 
with moderate pain due to RA were selected, and 
written consent of the patients was obtained for 
inclusion in the study. A total of 71 patients (40 
male, 31 female) 49 to 65 years of age were 
selected for the clinical study. Three groups of 20 
patients each were taken. Each group was 
administered one formulation (F1, F3 or F5). 
Eleven patients were kept on oral SR diclofenac 
(75 mg, po). The patients were randomized to 
receive drugs in a randomized crossover design, 
with a two-week washout period. Pain was 
assessed prior to treatment (baseline) and at 4, 
12, 24, 48, and 72 h after administration, using a 
10 point visual analogue scale (VAS, 0 `no pain' 




The results are expressed as the mean ± 
standard deviation (SD) using Student’s t-test 
and Origin 9 software. P < 0.02 was considered 
statistically significant. 
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The prepared transdermal patches of diclofenac 
were prepared and characterized. The effect of 
permeation enhancers was observed in the 
clinical studies.   
 
Physicochemical characteristics of 
transdermal patches 
 
The thickness, weight, folding endurance, and 
drug content of the prepared transdermal 
patches were determined (Table 2). 
 
The weight of patches (4 cm2) of different 
formulations ranged from 114 ± 0.40 to 132 ± 
0.24 mg. All transdermal films showed uniform 
thickness ranging from 0.245 ± 0.110 to 0.298 ± 
0.048 mm. Folding endurance ranged from 149 ± 
9.09 to 192 ± 10.12. All transdermal films 
showed high and uniform drug content (ranging 
from 94.40 ± 1.04 to 98.62 ± 1.08%). 
 
Ex vivo permeation  
 
Ex vivo permeation across the rat abdominal skin 
was increased with the use of permeation 
enhancers (Figure 1). 
 
The percent drug permeated was increased with 
a high proportion of permeation enhancers, with 
the best permeation shown by F3 (with 
turpentine oil). At the end of the 24 h study, the 
drug permeation was 45.48, 58.89, 65.54, 56.29, 
and 60.50 % for formulation F1, F2, F3, F4 and 
F5, respectively. It was evident that the 
permeation effect of turpentine oil was better 
than that of sesame oil.  
 
Primary skin irritation  
 
The use of the patch did not show any erythema 
and edema at the site of application based on 
primary skin irritation tests (after 48 h). Thus, the 




Figure 1: Ex vivo drug permeation of diclofenac in pH 
7.4 phosphate buffer in a modified Franz diffusion cell 
from the transdermal patch formulation F1 -●-; F2 -□-; 
F3 -∆-; F4 -×- and F5 -*-. 
 
Clinical analgesic effectiveness 
 
The VAS score of pain was studied in RA 
patients suffering from moderate to severe pain 
(pain score of 9 and above). The formulations 
F1, F3, and F5 were selected to study the 
effectiveness compared with the analgesic effect 
of the diclofenac sustained release (SR) tablet 
with VAS, which ranges from 0 `no pain' to 10 
`worst pain imaginable'. The pain score 
decreased continuously with the formulation 
containing permeation enhancers (F3 and F5). 
F3 decreased the pain score from 9.87 ± 1.14 to 
4.94 ± 0.78, while the SR tablet (once daily) 
decreased the pain score from 9.59 ± 0.42 to 
6.49 ± 1.20, 48-h post-administration (Figure 2).  
 
It was also noted that during the initial hours of 
the study, the SR tablet group showed better 
analgesia compared with the F1, F3, and F5 
groups. However, once the lag time was over 
and the drug started to diffuse properly across 
the skin, the patches group showed better 
activity. Moreover, the SR tablet was 
administered daily (once) while the patches were 
applied once to the subject under study.  
 
 
      Table 2: Physicochemical evaluation of transdermal films of diclofenac diethanolamine 
 








   F1 114±0.40 0.245±0.110 149±9.09 98.50±0.96 
   F2 124±0.20 0.272±0.012 184±12.06 98.62±1.08 
   F3 125±0.04 0.270±0.20 190±10.40 94.40±1.04 
   F4 129±0.24 0.298±0.048 179±9.20 98.01±1.08 
   F5 127±0.20 0.280±0.009 192±10.12 97.98±1.28 
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Figure 2: Pain score on the visual analogue scale (VAS) after application of the diclofenac patch in comparison 
with the diclofenac SR tablet (75 mg); formulation F1 (without permeation enhancer), F3 (with turpentine oil 1 % 
v/w as permeation enhancer), and F5 (with sesame oil 1 % v/w as permeation enhancer); the VAS ranges from 0 




The topical or transdermal delivery of drugs to 
patients with RA is known to improve patient 
compliance with immediate and prolonged 
release of the drug [4-6]. The use of a single 
patch for the whole day is expected to be more 
patient friendly compared with frequent oral 
dosing of tablets. As far as drug release was 
concerned, the permeation enhancers or the 
penetration enhancers play an important role in 
accelerating drug release across the skin (when 
included in the transdermal delivery systems). 
Transdermal delivery of drugs can be enhanced 
using chemical enhancers, iontophoresis, 
electroporation, ultrasound, microneedles, jet 
injection, and thermal poration [13,14,16,17]. Of 
these various methods of transdermal 
enhancement of drug permeation, the use of 
chemical enhancers is the best method of 
increasing transport across the skin. The method 
is simple to adopt and cost-effective.  
 
In this study, turpentine oil increased the 
permeation significantly compared with that of 
sesame oil. The increase was directly 
proportional to the concentration of turpentine oil 
and was in good agreement with previous 
studies [18-20]. Several groups have also 
reported turpentine oil and terpene-based 
enhancers as promising penetration enhancers 
with a greater effect on increasing the flux and 
anti-inflammatory activity [21,22]. The present 
study also found turpentine oil to be an effective 
penetration enhancer for transdermal drug 
delivery of diclofenac in the clinical study for films 
with penetration enhancers (F3 and F5), 
compared with that of films without enhancer 
(F1). The increasing concentration showed 
increased flux and increased analgesia.  
 
The data obtained from the clinical study also 
supported the ex vivo permeation study results. 
Thus, the enhanced permeation of drug across 
the skin showed greater analgesic activity, thus, 




The findings of this study reveal that turpentine 
oil and sesame oil are effective permeation 
enhancers in diclofenac transdermal films for use 
in patients with RA. However, turpentine oil is a 
better permeation enhancer than sesame oil. The 
results also show that the transdermal films of 
diclofenac with permeation enhancers may have 
greater therapeutic advantages over oral 
diclofenac tablets in terms of safety, prolonged 
release and improvement in patient compliance 
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